<DOC>
	<DOCNO>NCT03059160</DOCNO>
	<brief_summary>This single-center , exploratory , open-label study 10 girl diagnose Rett Syndrome . The study consist follow 4 part : Screening/Baseline run-in , Titration/Dose-Setting , Treatment , Washout/Follow-up .</brief_summary>
	<brief_title>Open Label Trial Triheptanoin ( UX007 ) Treatment Rett Syndrome .</brief_title>
	<detailed_description>1 . Screening baseline assessment ( 4 week first treatment ) : After parent sign inform consent , eligible patient undergo baseline assessment ( safety disease variable ) follow : - Physical examination - Vital sign : sit Blood Presure ( BP ) , Heart Rate ( HR ) respiratory rate , arm pit temperature . - Baseline height weight parameter - ECG ( ElectroCardioGraphy ) - 3-hour video EEG ( ElectroEncephaloGram ) - 24-hour NOX-T3 ( Portable Sleep Monitor ) record - QOL ( Quality Life ) Rett Syndrome-specific functional/severity questionnaires - Laboratory blood test , include endocrinology , hematology , biochemistry . - Parents request fill diary record daily basis seizure occurrence least 4 week first treatment . In addition ask record top 3 concern pertain care overall well-being patient . 2 . Treatment period ( 20 week ) : 1 . Initial final dose setting ( 2 week ) : UX007 titrate patient 2 week dose 1-4 gram per kilogram per day ( base age ) . If subject tolerate titrate 1-4 g/kg/day dose level , dose titrate maximum tolerate dose determined Investigator . At end Titration Period , subject maintain maximum UX007 dose achieve Titration Period duration study . The following assessment perform : â€¢ QOL RTT-specific functional/severity questionnaires 2 . Final dose ( 18 week ) : Patients receive dose UX007 determine Titration/Dose Setting period . They follow Investigator undergo safety disease-related assessment follow ( schedule outline protocol ) : - Physical examination - Vital sign ( sit BP , HR respiratory rate , oral temperature ) - Height weight parameter - ECG - 3-hour video EEG - 24-hour NOX record - Motor assessment - QOL RTT-specific functional/severity questionnaires - Laboratory blood test , include endocrinology , hematology , biochemistry . - Data collection parent ' diary 4 . Post-Washout Follow-up/End-of-Study : Within approximately six ( 6 ) week last dose administration , termination visit schedule . The following activity take place : - Physical examination - Vital sign ( sit BP , HR respiratory rate , oral temperature ) - Height weight parameter - ECG - 3-hour video EEG - 24-hour NOX record - Motor assessment - QOL RTT-specific functional/severity questionnaires - Laboratory blood test , include endocrinology , hematology , biochemistry . - Data collection parent 's diary - Decision regard continue administration UX007 patient benefit trial dechallenge period</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<criteria>Female patient age 5 to18 year ( inclusive ) . A classical diagnosis RTT , define accord internationally agree 2010 Rett Search criterion , MECP2 pathogenic mutation . Patients one following : At least 2 seizure per month per history fourweek baseline period accord parent diary per 3 hour video EEG record Walking ability , independent support Patients breathe abnormality record baseline NOX recording . Patients significant metabolic , liver , cardiac , respiratory morbidity relate RTT Patients significant liver , cardiac respiratory morbidity relate RTT</criteria>
	<gender>Female</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rett syndrome , Triheptanoic acid , Walking , EEG</keyword>
</DOC>